A curated list of organizations, funding mechanisms, and partnership models that enable healthcare startups and established firms to secure growth capital without issuing equity. This resource focuses on grants, collaborative R&D, licensing deals, and corporate venture arms that provide essential cash flow and market validation.
Get targeted exposure with custom position pinning and highlighted placement.
A federally mandated program encouraging domestic small businesses to engage in Federal Research/Research and Development (R/R&D) that has the potential for commercialization. It provides significant non-dilutive funding across NIH, DoD, and DOD agencies for innovative healthcare technologies.
Similar to SBIR but requires a formal collaboration between a small business and a non-profit research institution. This partnership model is ideal for healthcare firms seeking to leverage academic expertise while retaining full equity and securing federal R&D funding.
The primary source of biomedical and behavioral research funding in the United States. NIH provides competitive grants for basic and applied research, offering substantial non-dilutive capital to validate scientific hypotheses and advance therapeutic development.
A newer component of the SBIR program providing funding for early-stage, high-risk, high-reward research ideas. It allows healthcare innovators to explore novel medical technologies without investor dilution, focusing on feasibility and proof of concept.
While broader in scope, this organization offers specific health and wellness grants that can support community-based healthcare initiatives. These funds provide non-dilutive capital for programs addressing public health, elder care, and preventive medicine.
Major foundations often provide large, unrestricted or project-specific grants for global health initiatives. These partnerships offer significant capital for developing solutions in infectious diseases, maternal health, and sanitation without requiring equity stakes.
Large pharmaceutical and medical device companies often establish corporate venture arms that invest in startups. While some CVCs take equity, many form strategic partnerships focused on joint development agreements or exclusive licensing, providing capital and distribution channels.
Selected accelerators like Launch Academy or specialized healthcare incubators offer seed funding in the form of non-dilutive grants alongside mentorship. These programs help early-stage healthtech companies refine their business models before seeking equity investment.
Many states with strong healthcare clusters, such as California, Massachusetts, and New York, offer competitive grants to attract biotech firms. These non-dilutive funds support local job creation and innovation, providing crucial early-stage capital for growth.
The DoD funds research in areas like wound care, prosthetics, and medical readiness. Winning contracts provides guaranteed revenue streams and non-dilutive capital, validating the technology's efficacy for potential private sector adoption.
Partnering with larger firms to license patented healthcare technologies generates upfront payments and milestone-based royalties. This model monetizes intellectual property directly, providing capital without surrendering ownership or control of the core asset.
Forming formal research alliances with universities allows healthcare startups to access facility resources and shared grant funding. These partnerships often lead to co-funded studies, reducing out-of-pocket R&D costs while expanding technical capabilities.
Although technically debt, venture debt is a non-dilutive capital alternative used by healthcare startups with existing equity backing. It provides additional runway for product development or regulatory approval phases without further equity issuance.
Platforms like Kickstarter or Indiegogo allow healthcare innovators to pre-sell products or raise funds from future users. This non-dilutive method validates market demand while raising capital, though it requires careful regulatory compliance for medical claims.
While primarily a regulatory framework, government programs related to MDUF often include fee waivers or reduction opportunities for small businesses. These financial incentives reduce the cost of market entry, effectively preserving capital that would otherwise be spent on fees.
Some angel groups structure deals as convertible notes or revenue-based financing, which are forms of debt rather than immediate equity dilution. This allows healthcare founders to access capital and mentorship while delaying equity valuation discussions.
Premier healthcare incubators sometimes offer residential programs that include cash stipends or operational credits in exchange for participation. This support covers overhead costs, allowing teams to focus on R&D without external equity pressure.
Governments partner with private healthcare firms to deliver services or develop infrastructure. These contracts provide steady, non-dilutive revenue streams based on performance metrics, sharing risk and reward between the public sector and private innovators.
A niche model where investors provide capital in exchange for a percentage of future sales rather than equity. This preserves founder control and aligns incentives around commercial success, appealing to late-stage healthtech companies nearing market launch.
Federal and state R&D tax credits can refund a significant portion of qualifying expenses. By leveraging these credits, healthcare companies can recover cash spent on clinical trials and drug development, effectively acting as non-dilutive capital injection.